Two new trials open for patients with B-cell lymphoma and chronic lymphocytic leukemiaChan Cheah
Two new phase I studies for patients with relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia have just opened at Linear Clinical Research.
Both explore new medicines with established mechanisms of action. TG-1701 is Btk inhibitor, and the bispecific engaging T-cell antibody mosentuzumab is a form of immunotherapy. They represent good options for eligible patients with B-cell lymphomas.